Bill & Melinda Gates Institute licenses 2 of Merck's TB antibiotic candidates

18 Oct 2022
www.fiercebiotech.com
CollaborateLicense out/in
Bill & Melinda Gates Institute licenses 2 of Merck's TB antibiotic candidates
Preview
Source: FierceBiotech
Patients who have drug-resistant forms of tuberculosis may have to endure longer and more complicated treatment.
Tuberculosis has become increasingly difficult to treat as antibiotic resistance rises and the pipeline of antibiotics in development thins out. Now, Merck & Co. and the Bill & Melinda Gates Medical Research Institute are teaming up to tackle the challenge, inking a global licensing deal for two preclinical tuberculosis (TB) antibiotics with hopes of combating resistance and cutting treatment times.
Patients who have drug-resistant forms of TB,  an infectious disease responsible for 1.5 million deaths each year, may have to endure longer and more complicated treatment, often with side effects. In efforts to create a shorter drug regimen against both drug-susceptible and drug-resistant TB forms, the Bill & Melinda Gates Medical Research Institute has snapped up the exclusive global license to two of Merck's preclinical antibacterial candidates.
The non-profit plans to assess the candidates, dubbed MK-7762 and MK-3854, to see if they could be used in new, affordable combo treatments for TB. Financial details of the deal were not disclosed.
The preclinical candidates were discovered by Merck scientists as part of the TB Drug Accelerator, a collaboration between eight Big Pharmas and numerous research organizations and universities to rapidly discover and develop new therapeutic candidates for the infectious disease.
In vitro and in vivo assessments of MK-7762 and MK-3854 demonstrated potent antibacterial activity against the organism that causes TB, including some strains that are resistant to current treatments, according to an Oct. 18 release.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.